Literature DB >> 8431016

Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

R A Fromtling1, J N Galgiani, M A Pfaller, A Espinel-Ingroff, K F Bartizal, M S Bartlett, B A Body, C Frey, G Hall, G D Roberts.   

Abstract

Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 10(4) and 2.5 x 10(3) cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87% for different inocula, times of incubation, and end point criteria. Agreement was maximized (85%) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC-2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee Report, Vol. 5, No. 17, 1988; M. A. Pfaller, L. Burmeister, M. S. Bartlett, and M. G. Rinaldi, J. Clin. Microbiol. 26:1437-1441, 1988; M. A. Pfaller, M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B.A. Body, A. Espinel-Ingroff, R.A. Fromtling, G.S. Hall, C.E. Hughes, F. C. Odds, and A. M. SUgar, J. Clin. Microbiol. 34:1648-1654, 1990), these findings will be used by the National Committee for Clinical Laboratory Standards to develop a standardized method for in vitro antifungal susceptibility testing for yeasts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431016      PMCID: PMC187601          DOI: 10.1128/AAC.37.1.39

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Prophylactic fluconazole and Candida krusei infection.

Authors:  R O Casasnovas; D Caillot; E Solary; B Bonotte; P Chavanet; A Bonin; P Camerlynck; H Guy
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

3.  Fluconazole resistance in AIDS patients.

Authors:  L Willocks; C L Leen; R P Brettle; D Urquhart; T B Russell; L J Milne
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

4.  Fluconazole and Candida krusei fungemia.

Authors:  D A Persons; M Laughlin; D Tanner; J Perfect; J P Gockerman; J W Hathorn
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

5.  Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.

Authors:  M Akova; H E Akalin; O Uzun; D Gür
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

6.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

7.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

8.  Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study.

Authors:  T J Walsh; M Rubin; J Hathorn; J Gress; M Thaler; J Skelton; J McKnight; M Browne; D Marshall; D Cotton
Journal:  Arch Intern Med       Date:  1991-04

9.  Collaborative investigation of variables in susceptibility testing of yeasts.

Authors:  M A Pfaller; M G Rinaldi; J N Galgiani; M S Bartlett; B A Body; A Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

10.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; T M Kerkering; P R Goldson; S Shadomy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

View more
  70 in total

1.  Susceptibility testing of Malassezia species using the urea broth microdilution method.

Authors:  Y Nakamura; R Kano; T Murai; S Watanabe; A Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes.

Authors:  Belkys Fernández-Torres; Francisco J Cabañes; Alfonso J Carrillo-Muñoz; Alexandre Esteban; Isabel Inza; Lourdes Abarca; Josep Guarro
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.

Authors:  R K Li; C M Elie; G E Clayton; M A Ciblak
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Antimicrobial activity of some Indian medicinal plants.

Authors:  Rajesh Dabur; Amita Gupta; T K Mandal; Desh Deepak Singh; Vivek Bajpai; A M Gurav; G S Lavekar
Journal:  Afr J Tradit Complement Altern Med       Date:  2007-02-16

5.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Effects of temperature on anti-Candida activities of antifungal antibiotics.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole.

Authors:  J H Rex; M A Pfaller; M Lancaster; F C Odds; A Bolmström; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.

Authors:  M A Pfaller; M Bale; B Buschelman; M Lancaster; A Espinel-Ingroff; J H Rex; M G Rinaldi; C R Cooper; M R McGinnis
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.